FDA Grants Breakthrough Therapy Designation to Abatacept for Acute GVHD Prevention

The FDA granted a breakthrough therapy designation to abatacept for the prevention of moderate to severe acute graft-versus-host disease in hematopoietic stem cell transplants from unrelated donors.

Source: CancerNetwork - December 4, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news